Trial Profile

A Phase II Study of RAD001 in the Treatment of Patients With Plexiform Neurofibromas (PN) Associated With Neurofibromatosis Type 1 (NF1).

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 26 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Neurofibromatosis 1; Plexiform neurofibroma
Focus Adverse reactions; Therapeutic Use
Sponsors Novartis

Most Recent Events

10 May 2016 Study phase changed from phase IV to phase II, adverse events added as primary endpoint hence trial focus changed from TU to TU + AR.
10 May 2016 Status changed from completed to discontinued due to poor patients' accrual.
24 Jun 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com